4 results
The primary objective of this study is to compare PFS with LY2875358 plus erlotinib therapy with erlotinibmonotherapy as first-line treatment in metastatic NSCLC patients with activating EGFR mutations who havedisease control after an 8-week lead-in…
In oral FXa inhibitor-treated patients with acute intracranial bleeding, the objectives of this study are as follows:Primary Efficacy Objective:• To evaluate the effect of andexanet versus usual care on the rate of effective hemostasis.Secondary…
In oral FXa inhibitor-treated patients with acute intracerebral bleeding, the objectives of this study are as follows:Primary Efficacy Objective:To evaluate the effect of andexanet versus usual care on the rate of effective hemostasis.Secondary…
To evaluate the safety, effectiveness and performance of the DESyne BDS Plus DECSS (Test) as compared to the CE Mark approved DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2 NECSS; DESyne X2) (Control) in the treatment of de novo native…